PURE Bioscience to Present at the 11th Annual LD Micro Conference
SAN DIEGO--(BUSINESS WIRE)--Nov 20, 2018--PURE Bioscience, Inc. ( OTCQB: PURE ), creator of the patented, non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today announced that Hank R. Lambert, CEO, will present at the 11 th Annual LD Micro Conference on Wednesday, December 5 th at 11:00 am PT, at the Luxe Hotel Sunset Boulevard in Los Angeles.
Lambert will discuss the Company’s dual path strategy to establish PURE’s non-toxic SDC antimicrobial technology as a novel and proprietary food safety solution (effective against pathogens including Salmonella, E. coli, Listeria and Norovirus):EPA registered PURE® Hard Surface disinfectant FDA approved PURE Control® direct food contact processing aid
The presentation will be webcast live and slides may be accessed on the Company’s website, http://www.purebio.com/investors/events-presentations/. The presentation will be archived for 90 days.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit, and Main Event). In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe. For those interested in attending, please contact David Scher at email@example.com or visit www.ldmicro.com for more information.
About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena -- providing solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and it mitigates bacterial resistance. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Statements in this press release concerning the company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company’s current and future products and services in the marketplace, including the Company’s ability to convert successful evaluations and tests for PURE Control into customer orders and customers continuing to place product orders as expected and to expand their use of the Company’s products; the Company’s ability to raise the funding required to support its continued operations and the implementation of its business plan; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw meat processing and to expand its use in OLR poultry processing; competitive factors, including customer acceptance of the Company’s SDC-based products that are typically more expensive than existing treatment chemicals; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2018 and Form 10-Q for the third fiscal quarter ended September 30, 2018. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181120005153/en/
CONTACT: Hank Lambert, CEO
PURE Bioscience, Inc.
619-596-8600 ext. 103
firstname.lastname@example.orgTerri MacInnis, VP of IR
Bibicoff + MacInnis, Inc.
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY OTHER HEALTH RESEARCH SCIENCE
SOURCE: PURE Bioscience, Inc.
Copyright Business Wire 2018.
PUB: 11/20/2018 08:36 AM/DISC: 11/20/2018 08:35 AM